Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Greillier · SciRah

Researcher profile · Semantic Scholar

L. Greillier

Share profile

L. Greillier — researcher profile on SciRah

h-index: 44
Works: 563
Citations: 11K

Most-cited papers

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
N. Leighl, H. Akamatsu, Sun M. Lim, Ying Cheng +44 more
2024Journal of Clinical Oncology105 citations Open access
Semantic Scholar
LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
G. Goss, G. Darling, V. Westeel, K. Nakagawa +16 more
2024Annals of Oncology43 citations Open access
Semantic Scholar
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial.
E. Felip, S. Popat, U. Dafni, K. Ribi +21 more
2025Annals of Oncology29 citations Open access
Semantic Scholar
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
Arthur Géraud, Paul Gougis, A. de Nonneville, Mathilde Beaufils +17 more
2025Cancer Treatment Reviews24 citations
Semantic Scholar
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
J. Yang, Meng-Zhao Wang, L. Doucet, Yun Fan +44 more
2025Journal of Clinical Oncology23 citations
Semantic Scholar
A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.
J. Yang, L. Doucet, Meng-Zhao Wang, Yun Fan +16 more
2024Journal of Clinical Oncology23 citations Open access
Semantic Scholar
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
O. Bylicki, F. Guisier, A. Scherpereel, C. Daniel +16 more
2024Lung Cancer21 citations Open access
Semantic Scholar
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.
G. Goss, G. Darling, Virginie Westeel, Kazuhiko Nakagawa +24 more
2026Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial.
J. Remon, P. Bironzo, Nicolas Girard, L. Bigay-Game +16 more
2025The Lancet Oncology14 citations Open access
Semantic Scholar
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
D. Spigel, Virginie Westeel, I. C. Anderson, L. Greillier +20 more
2025The Lancet Respiratory Medicine12 citations Open access
Semantic Scholar
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Cai-Cun Zhou, L. Greillier, Geoffrey Liu, Thomas John +26 more
2026New England Journal of Medicine11 citations
Semantic Scholar
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Lyria Amari, P. Tomasini, E. Dantony, G. Rousseau-Bussac +16 more
2024Lung Cancer8 citations Open access
Semantic Scholar
Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.
N. Girard, B. Besse, M. Duruisseaux, L. Greillier +15 more
2025Journal of Clinical Oncology7 citations
Semantic Scholar
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
Yan Xu, J. Yang, Yan-Qiu Zhao, L. Doucet +46 more
2025Cell Reports Medicine6 citations Open access
Semantic Scholar
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial
G. Levallet, C. Créveuil, Alexandre Léger-Vigot, S. Brosseau +14 more
2025Translational Oncology5 citations Open access
Semantic Scholar
Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study
B. Mennecier, J. Khalifa, R. Descourt, L. Greillier +2 more
2024BMC Cancer5 citations Open access
Semantic Scholar
LBA3: Sites of relapse and subsequent therapy in the BR.31 phase III study of durvalumab vs placebo in resected stage IB-IIIA NSCLC
V. Westeel, G. Goss, G. Darling, K. Nakagawa +16 more
2025Journal of Thoracic Oncology4 citations
Semantic Scholar
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
A. Bronstein, H. Curcio, Isabelle Monnet, C. Ricordel +16 more
2025Clinical Lung Cancer4 citations Open access
Semantic Scholar
LBA68 CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses
G. Goss, G. Darling, V. Westeel, K. Nakagawa +16 more
2025Annals of Oncology4 citations
Semantic Scholar
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort
S. Nannini, F. Guisier, H. Curcio, C. Ricordel +6 more
2024Current Oncology4 citations Open access
Semantic Scholar
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Marion Ferreira, A. Swalduz, L. Greillier, P. du Rusquec +18 more
2024Lung Cancer4 citations Open access
Semantic Scholar
Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
J. Heymach, Geoffrey Liu, L. Xing, L. Greillier +16 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
OA05.02 First-Line Atezolizumab Plus Chemotherapy in Elderly Patients With Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial
C. Mascaux, L. Greillier, L. Moreau, T. Egenod +16 more
2025Journal of Thoracic Oncology3 citations Open access
Semantic Scholar
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study.
Thomas Pierret, L. Greillier, F. Guisier, C. Daniel +16 more
2025Lung Cancer3 citations
Semantic Scholar
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
K. Rohrberg, I. Melero, M. Sanmamed, Eva Muñoz-Couselo +35 more
2026Journal for ImmunoTherapy of Cancer2 citations Open access
Semantic Scholar
An integrative multimodal machine learning signature of primary resistance to immunotherapy in advanced non-small cell lung cancer: biomarker analysis from the PIONeeR study
F. Barlesi, F. Monville, L. Greillier, N. Ngoi +31 more
2026medRxiv2 citations Open access
Semantic Scholar
ROOFS: RObust biOmarker Feature Selection
A. Bakhmach, Paul Dufoss'e, A. Vaglio, F. Monville +3 more
2026BMC Bioinformatics2 citations
Semantic Scholar
Abstract CT231: Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC
F. Barlesi, T. Csőszi, R. Duchnowska, T. Egenod +10 more
2026Cancer Research2 citations
Semantic Scholar
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
V. Gounant, L. Greillier, C. Mascaux, F. Pinquie +19 more
2025JTO Clinical and Research Reports2 citations Open access
Semantic Scholar
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study
F. Ghiringhelli, Y. Lawrence, E. Felip, A. Zer +10 more
2025Journal for ImmunoTherapy of Cancer2 citations Open access
Semantic Scholar
29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial
H. Lena, L. Paz-Ares, H. Harputluoglu, E. Wauters +14 more
2025Journal of Thoracic Oncology2 citations
Semantic Scholar
137P Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker
S. Salas, L. Nguyen Phuong, F. Ginot, L. Greillier +5 more
2024Annals of Oncology2 citations
Semantic Scholar
Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors
A. Italiano, Teresa García Manrique, Enrique Grande Pulido, K. Kerrigan +16 more
2026Frontiers in Oncology1 citations Open access
Semantic Scholar
Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study group.
G. Justeau, L. Greillier, F. Viñas, L. Falchero +16 more
2026Chest1 citations
Semantic Scholar
239MO: Stratification of pleural mesothelioma patients for combined immunotherapy based on sarcomatoid component and tumour microenvironment markers in the IFCT-MAPS2 study
G. Tosato, Y. Blum, J-B. Assié, R. Sequeiros +15 more
2025Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
P1.17.21 Gender Disparities in Remote Patient Monitoring: Analysis From 973 Lung Cancer Patients Treated Across 42 Sites in France and Belgium
C. Parisi, L. Greillier, C. Audigier-Valette, J. Pluvy +13 more
2025Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors
Linh Nguyen Phuong, F. Fina, L. Greillier, P. Tomasini +8 more
20251 citations
Semantic Scholar
FIRST-NEC (GFPC 01-2022): A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with advanced large-cell neuroendocrine lung carcinomas (LCNECs).
D. Arpin, J. Gautier, A. Mansuet-Lupo, Romain Corre +16 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
EP.04C.04 Extended Inclusion Criteria for Lung Cancer Screening to Tabacco Related Diseases: Comparison of Preliminary Results in Two Prospective Cohorts
E. Armand, P. Habert, P. Thomas, X. D'Journo +17 more
2024Journal of Thoracic Oncology1 citations
Semantic Scholar
120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial
K. Cuppens, G. L. Russo, O. J. Juan Vidal, E. Felip +16 more
2024Immuno-Oncology and Technology1 citations Open access
Semantic Scholar
Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional study.
Arnaud De Gunten, A. Mogenet, A. Bronstein, E. Pollien +6 more
2026Lung Cancer0 citations Open access
Semantic Scholar
CEMI-LUNG, an observational study to assess cemiplimab effectiveness and safety in patients with advanced non-small cell lung cancer in real-world clinical practice in Europe
H. Wustefeld, L. Greillier, K. Blazejczyk, B. Mennecier +9 more
2026Pneumologie0 citations
Semantic Scholar
Clinical efficiency of remote symptom monitoring using electronic patient-reported outcome (ePRO) in lung cancer: Results of the prospective, multicenter REAL-MOOV-LUNG trial.
N. Girard, S. Dureau, B. Godbert, M. Massiani +12 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Combined emphysema and cancer, from radiology to prognosis in patients treated by immunotherapy: An ancillary study of a prospective multicenter phase II IFCT-1802 SAVIMMUNE.
Maéva Zysman, I. Benlala, A. Langlais, L. Greillier +18 more
2026Respiratory medical research0 citations
Semantic Scholar
Specific dendritic cells spatial organization is associated to ICB Response in Non–Small-Cell Lung Cancer
E. Gobbini, Pierre Duplouye, Marcelo Hurtado, A. Doffin +30 more
2026bioRxiv0 citations
Semantic Scholar
Multimodality Stacking with Blockwise missing values and application to the PIONeeR biomarkers study for prediction of resistance to immunotherapy
M. Boussena, F. Monville, J. Fieschi-Meric, F. Vely +7 more
2026arXiv.org0 citations
Semantic Scholar
Using the Geriatric Core Dataset (G-CODE) to predict mortality in older patients with cancer: development and external validation.
A. Couderc, C. Martinez-Tapia, Simone Mathoulin-Pélissier, M. Laurent +10 more
2026British Journal of Cancer0 citations Open access
Semantic Scholar
Comparative effectiveness in MET ex14 NSCLC: Outcomes from a propensity score–based analysis of 8 pooled real-world datasets (the TOGETHER study).
L. Greillier, F. Guisier, P. Christopoulos, Simon Ekman +15 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Single-center retrospective cohort study of lung cancer associated with interstitial lung disease: Prognostic factors and molecular profile.
A. Goga, G. Soussi, A. Mogenet, P. Habert +12 more
2026Lung Cancer0 citations Open access
Semantic Scholar
Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study
Thomas Pierret, J. Auliac, C. Ricordel, Catherine Daniel +12 more
2026Current Oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Audigier-Valette×8
Invite
C. Audigier-Valette — researcher profile on SciRah
O. Bylicki×8
Invite
O. Bylicki — researcher profile on SciRah
F. Guisier×7
Invite
F. Guisier — researcher profile on SciRah
A. Toffart×7
Invite
A. Toffart — researcher profile on SciRah

×6

Invite

E. Felip — researcher profile on SciRah

Invite

C. Ricordel — researcher profile on SciRah

Invite

V. Westeel — researcher profile on SciRah

Invite

P. Tomasini — researcher profile on SciRah

Invite

H. Curcio — researcher profile on SciRah

Invite

Thomas John — researcher profile on SciRah

Invite

M. Stockler — researcher profile on SciRah

Invite

L. Doucet — researcher profile on SciRah